Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPITL: Combined Drug Approach to Prevent Ischemia-Reperfusion Injury During Liver Transplantation
2012-001960-31Phase 2Completed
- Sponsor
- UZ Leuven
- Start
- Feb 2013
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of melatonin, epoprostenol, antithrombin III concentrate, epoetin beta, C1 inhibitor, human and 5 more in hepatic ischemia-reperfusion injury (HIRI) and liver transplant, sponsored by UZ Leuven. Primary endpoint: Log-transformed peak AST within 72 hours post-transplant. Started Feb 2013; status: completed.
02
Drugs
melatoninepoprostenolantithrombin III concentrateepoetin betaC1 inhibitor, human
03
Conditions
hepatic ischemia-reperfusion injury (HIRI)liver transplant
Beyond the preview
Go deeper on 2012-001960-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001960-31.